^Hirst, WD; Stean, TO; Rogers, DC; Sunter, D; Pugh, P; Moss, SF; Bromidge, SM; Riley, G; Smith, DR (2006). „SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models”. European Journal of Pharmacology. 553 (1–3): 109—19. PMID17069795. doi:10.1016/j.ejphar.2006.09.049.
^Wesołowska, A; Nikiforuk, A (2007). „Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression”. Neuropharmacology. 52 (5): 1274—83. PMID17320917. doi:10.1016/j.neuropharm.2007.01.007.
^Wesołowska, A (2008). „The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors”. European Journal of Pharmacology. 580 (3): 355—60. PMID18096153. doi:10.1016/j.ejphar.2007.11.022.
^Wesołowska, A; Nikiforuk, A (2008). „The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats”. European Journal of Pharmacology. 582 (1–3): 88—93. PMID18234190. doi:10.1016/j.ejphar.2007.12.013.
^Li, Z; Huang, M; Prus, AJ; Dai, J; Meltzer, HY (2007). „5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus”. Brain Research. 1134 (1): 70—8. PMID17207474. doi:10.1016/j.brainres.2006.11.060.